Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC86WO
|
|||
| Drug Name |
ION839
|
|||
| Synonyms |
AZD2693
Click to Show/Hide
|
|||
| Drug Type |
Ligand-conjugated antisense
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [1] | |
| Company |
Ionis; AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05809934) A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.